ISTH Grant Medal for Frits Rosendaal: Thrombosis & Hemostasis

The intersection of genetic predisposition and cardiovascular risk has long been one of the most complex frontiers in medicine. The announcement that Professor Frits Rosendaal will receive the 2026 ISTH Robert P. Grant Medal is more than a professional accolade; it is a recognition of the epidemiological rigor that shifted how the global medical community understands, diagnoses, and prevents venous thromboembolism (VTE).

To understand the significance of this award, one must look at the specific nature of Rosendaal’s contributions. While many researchers focus on the molecular mechanics of clotting in a vacuum, Rosendaal utilized clinical epidemiology to bridge the gap between the lab and the general population. His instrumental role in the discovery of Factor V Leiden—the most common inherited risk factor for thrombophilia—transformed the approach to personalized medicine. It allowed clinicians to move away from a “one size fits all” treatment model toward risk-stratified prevention.

Furthermore, his research into the relationship between oral contraceptives and venous thrombosis provided essential safety data that continues to influence prescribing guidelines and patient counseling worldwide. By quantifying these risks through large-scale studies, Rosendaal provided the evidence base necessary to balance the benefits of hormonal contraception with the necessity of patient safety.

The Robert P. Grant Medal itself carries a legacy of internationalism, named after the cardiologist who fostered American-European collaboration. Rosendaal has mirrored this spirit, not only through his academic output but through his leadership as Council Chair and Editor-in-Chief of the Journal of Thrombosis and Haemostasis (JTH). His push for a professional Executive Director and the creation of World Thrombosis Day indicates a strategic shift in the field: moving from purely academic discourse to active public health advocacy.

Forward Look: The Future of Thrombosis Management

Looking ahead, the influence of Rosendaal’s epidemiological approach is likely to accelerate the transition toward precision hematology. As we move toward 2026 and beyond, we can expect three primary trends to emerge from the foundation he helped build:

First, the integration of polygenic risk scores. Building on the discovery of Factor V Leiden, the next frontier is understanding how multiple minor genetic variants interact with environmental triggers to cause clotting.

Second, a heightened focus on “preventative epidemiology.” With the infrastructure of World Thrombosis Day now firmly in place, the goal will shift from treating clots after they occur to implementing systemic screening protocols in high-risk populations.

Finally, as the Grant Medal will be presented in Paris in 2026, the event is expected to serve as a catalyst for new transatlantic research partnerships, emphasizing the continued necessity of global data sharing to tackle cardiovascular disorders on a planetary scale.